JILL LAIBINIS: Open Payments
NPI 1689397754 · WILKES BARRE, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,979 in 100 payments from 12 companies in 2025. Trend: 2023 $585 · 2024 $1,057 · 2025 $1,979
Food & beverage: $1,979
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 16 | $512 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $305 |
| Janssen Pharmaceuticals, Inc | 9 | $251 |
| ABBVIE INC. | 15 | $196 |
| Otsuka America Pharmaceutical, Inc. | 10 | $177 |
| Neurocrine BioSciences, Inc. | 13 | $145 |
| Alkermes, Inc. | 8 | $145 |
| E.R. Squibb & Sons, L.L.C. | 10 | $145 |
| Vanda Pharmaceuticals Inc. | 2 | $34 |
| Supernus Pharmaceuticals, Inc. | 2 | $31 |
Products named: UZEDY, CAPLYTA, INVEGA SUSTENNA, VRAYLAR, AUSTEDO XR, INGREZZA, COBENFY, ARISTADA.
Industry payments across PA — which companies pay providers there.
